Genpact Limited G is benefiting from its investor-friendly steps and strong clientele.G’s earnings and revenues for 2022 are expected to improve 11.8% and 8.2%, respectively, from the corresponding year-ago reported figures.Factors That Augur WellGenpact is benefiting from a strong clientele worldwide. The company serves almost one fourth of the Global Fortune 500, including big names such as AstraZeneca, Novartis, Bayer, Dentsu, AXA, Hitachi, Konica Minolta, Heineken, Santander, Synchrony Financial and Sysco. The company's Global Client base has improved rapidly over the last five years (2016-2021) with revenues increasing at a healthy CAGR of 10.5% to reach $3.65 billion in 2021. Global Clients, as a percentage of total revenues, increased from approximately 86% in 2016 to approximately 91% in 2021. We believe that Genpact’s expertise in providing BPO services will continue to expand customer base in the long run.We are impressed with Genpact’s endeavours in returning value to shareholders in the form of share repurchases and dividend payments. During 2021, 2020 and 2019, Genpact repurchased shares worth $298.2 million, $137.1 million and $30 million, respectively. The company paid $80.5 million, $74.2 million and $64.7 million in dividends to its shareholders during 2021, 2020 and 2019, respectively. Such shareholder-friendly moves indicate the company’s commitment to create value for shareholders and underline its confidence in its business.A Key RiskGenpact's current ratio at the end of third-quarter 2022 was pegged at 1.08, lower than the current ratio of 1.58 reported at the end of third-quarter 2021 and the prior-year quarter’s 1.58. Decreasing current ratio does not bode well for the company.Shares of G have decreased 6.6% in the past year against 4.6% growth of the industry it belongs to.Genpact Limited Price and EPS Surprise Genpact Limited price-eps-surprise | Genpact Limited QuoteZacks Rank and Stocks to ConsiderGenpact currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Some better-ranked stocks in the broader Zacks Business Services sector are Booz Allen Hamilton Holding Corporation BAH and Cross Country Healthcare, Inc. CCRN.Booz Allen carries a Zacks Rank #2 (Buy) at present. BAH has a long-term earnings growth expectation of 8.9%.Booz Allen delivered a trailing four-quarter earnings surprise of 8.8%, on average.Cross Country Healthcare is currently Zacks #2 Ranked. CCRN has a long-term earnings growth expectation of 6%.CCRN delivered a trailing four-quarter earnings surprise of 10.1%, on average. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Genpact Limited (G): Free Stock Analysis Report Booz Allen Hamilton Holding Corporation (BAH): Free Stock Analysis Report Cross Country Healthcare, Inc. (CCRN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research